Immunotherapy after esophageal cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests whether continuing immunotherapy (toripalimab) after surgery helps prevent esophageal cancer from coming back. It is for people who already had surgery for squamous cell esophageal cancer after receiving immunotherapy plus chemotherapy before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have had surgery to remove esophageal cancer (a type of squamous cell carcinoma) that was potentially curable.
- Before surgery, you must have received at least 2 cycles of immunotherapy combined with chemotherapy.
- Your cancer must have been completely removed (called R0 resection) and you must have no known remaining cancer.
- Your overall health must be good, with adequate blood counts and liver/kidney function (no severe organ damage).
- You must not have had any other cancer (except some cured early-stage prostate or skin cancers) or active infections like hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug toripalimab and the chemotherapy pill capecitabine after standard chemoradiotherapy can help prevent esophageal cancer from coming back. It's for people with squamous cell esophageal cancer that hasn't spread far and who have just finished chemoradiotherapy.
This trial tests whether an immunotherapy drug called toripalimab, given after surgery, can help prevent esophageal cancer from returning in people whose cancer completely disappeared after chemo or radiation and surgery. If you already had a complete response, this treatment might lower the risk of the cancer coming back.
This trial tests a new combination of immunotherapy (toripalimab) with two chemotherapy drugs before surgery for esophageal cancer, compared to a standard chemo regimen. The goal is to see if the new combination improves outcomes for patients with resectable tumors.
This trial tests whether continuing a type of immunotherapy (toripalimab) after standard chemoradiation helps keep advanced esophageal cancer from growing, compared to just watching and waiting. If you've already completed initial treatment without the cancer getting worse, this study might help you stay stable longer.
This trial tests a new immunotherapy drug called toripalimab, given before, during, and after standard radiation and chemotherapy for esophageal cancer that hasn't spread. The goal is to see if adding this drug can improve outcomes for patients.
This study tests whether giving additional immunotherapy after esophageal cancer surgery can help prevent the cancer from coming back. If you've already had chemotherapy and immunotherapy before surgery, this trial may offer a way to continue that benefit after your operation.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.